HOMOLOGY MEDICINES ALERT: Bragar Eagel & Squire, P.C. is Investigating Homology Medicines, Inc. on Behalf of Homology Stockholders and Encourages Investors to Contact the Firm


NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Homology Medicines (NASDAQ: FIXX) on behalf of Homology stockholders. Our investigation concerns whether Homology has violated the federal securities laws and/or engaged in other unlawful business practices.

Click here to participate in the action.

On July 21, 2020, Mariner Research (“Mariner”) published a report questioning statements by Homology and its officers about the efficacy of HMI-102, the Company’s lead product candidate for treatment of phenylketonuria. Mariner focused on Homology’s HMI-102 dose escalation pheNIX trial, concluding that the Company concealed data showing HMI-102’s lack of efficacy and indicating that the program was unlikely to proceed to commercialization. Among other evidence, Mariner cited an email from Homology’s Chief Communications Officer appearing to indicate the Company’s awareness that a HMI-102 high dose patient had adverted to the adverse efficacy issue in a social media post during April 2020.

On this news, Homology’s stock price fell $1.71 per share, or 10.38%, over the following three trading days, closing at $14.77 per share on July 24, 2020.

If you purchased or otherwise acquired Homology shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
Marion Passmore, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com